An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Edwards Lifesciences (NYSE: EW) will release its Q1 2024 operating results on April 25, 2024, followed by a conference call to discuss the results. Investors can dial in or access the call through the company's Investor Relations website.
Edwards Lifesciences (NYSE: EW) pubblicherà i risultati operativi del primo trimestre 2024 il 25 aprile 2024, seguiti da una conferenza telefonica per discutere i risultati. Gli investitori possono partecipare alla chiamata telefonicamente o accedendo alla conferenza tramite il sito web delle Relazioni con gli Investitori della società.
Edwards Lifesciences (NYSE: EW) dará a conocer los resultados operativos del primer trimestre de 2024 el 25 de abril de 2024, seguidos de una conferencia telefónica para discutir los resultados. Los inversores pueden unirse a la llamada por teléfono o acceder a la conferencia a través del sitio web de Relaciones con Inversores de la empresa.
에드워즈 라이프사이언스 (NYSE: EW)는 2024년 4월 25일에 2024년 1분기 운영 결과를 발표할 예정이며, 그 결과에 대해 논의하기 위한 컨퍼런스 콜이 이어질 것입니다. 투자자들은 전화를 통해 참여하거나 회사의 투자자 관계 웹사이트를 통해 컨퍼런스 콜에 접속할 수 있습니다.
Edwards Lifesciences (NYSE: EW) publiera ses résultats opérationnels du premier trimestre 2024 le 25 avril 2024, suivis d'une conférence téléphonique pour discuter des résultats. Les investisseurs peuvent se joindre à l'appel par téléphone ou accéder à la conférence via le site Internet des Relations Investisseurs de l'entreprise.
Edwards Lifesciences (NYSE: EW) wird am 25. April 2024 die Betriebsergebnisse für das erste Quartal 2024 veröffentlichen, gefolgt von einer Telefonkonferenz zur Erörterung der Ergebnisse. Investoren können sich telefonisch einwählen oder über die Investor Relations-Website des Unternehmens an der Konferenz teilnehmen.
Positive
None.
Negative
None.
IRVINE, Calif.--(BUSINESS WIRE)--
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com.
About Edwards Lifesciences
Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, X and YouTube.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
Media Contact: Amy Hytowitz, 949-250-4009
Investor Contact: Mark Wilterding, 949-250-6826
Source: Edwards Lifesciences Corporation
Edwards Lifesciences will announce its Q1 2024 operating results on April 25, 2024.
The earnings conference call hosted by Edwards Lifesciences will take place on April 25, 2024.
Investors can participate in the conference call hosted by Edwards Lifesciences by dialing (877) 704-2848 or (201) 389-0893.
The conference call hosted by Edwards Lifesciences can be accessed live and archived on the 'Investor Relations' section of the Edwards website at ir.edwards.com.
edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.
